Dermatology image datasets: clinical context, lesion labels and permissions Understand skin image datasets, ISIC release terms, lesion grouping, diagnostic evidence, commercial source options and careful sample evaluation. Dermatology image datasets contain skin photographs or specialist images linked to lesion, encounter or diagnostic information for a defined task. Dermoscopy, close-up clinical photography and total-body image crops differ in appearance and context. Buyers should specify acquisition style, patient and lesion grouping, label evidence, image quality and permitted use before comparing collections. A public research release may include differently licensed subsets, and its labels do not automatically establish suitability for a clinical product. Fiund can assess a skin-image sourcing brief and potential authorized sources, with feasibility, documentation, access, preparation and commercial terms confirmed for the selected project. Capture types Dermoscopy, clinical close-up, total-body crops and paired views Group carefully Patient, encounter, lesion and repeated image relationships Public reference ISIC releases have different sizes and licenses Critical review Diagnostic evidence, uncertainty and acquisition distribution Skin images are not a single visual distribution Dermoscopy provides a specialized view that differs from a phone photograph or a crop extracted from total-body photography. Lighting, scale, contact or non-contact acquisition, polarization, visible surrounding skin and post-processing can all change the task. A buyer should name the expected input and whether the model receives one lesion crop, multiple views, contextual photographs or accompanying clinical metadata. Do not assume that a successful dermoscopy experiment establishes performance on ordinary consumer photos. Define the output as well. Lesion classification, localization, segmentation, image-quality assessment and longitudinal comparison require different labels and pairing. A binary malignancy label is not equivalent to a detailed diagnostic taxonomy. Repeated images of the same lesion can be useful for change analysis but are strongly correlated for evaluation. Preserve patient, lesion and encounter relationships instead of treating every image as an independent clinical case. If those relationships are unknown, record the limitation. ISIC demonstrates why release-specific licensing matters The [ISIC challenge data page](https://challenge.isic-archive.com/data/) identifies a 2024 SLICE-3D release with 401,059 image crops under a noncommercial license and a separately identified permissive subset with 217,477 images under CC-BY. A buyer must not combine the broad release count with the permissive subset’s terms to imply that all files have identical commercial permissions. Count, version and license should travel together in a comparison table. The [ISIC access FAQ](https://www.isic-archive.com/blank-1) also explains that permissions are assigned at the image level and that hidden private test material is not available by special request. These are useful boundaries when describing public resources. ISIC is a reference for task design and research comparison, not a statement that Fiund owns the source images or can relicense private clinical material. A public dataset’s existence does not establish the feasibility of an unrelated sourcing request. Source/capture family Potential value Essential caution Dermoscopic images Specialist lesion appearance and fine structures Device/capture setup differs from phone photos Clinical close-ups More ordinary photographic context Focus, scale and lighting can vary widely Total-body crops Many lesion observations within a defined workflow Crops and repeated patients are correlated Paired modalities Relating dermoscopic and clinical appearance Pairing must refer to the same lesion/encounter Longitudinal imagery Visible change over time Time, lesion identity and intervention context matter Buyer roles and evidence of need Potential users include dermatology researchers, image-quality teams, skin-imaging developers and evaluation groups. These are use-case segments, not verified Fiund customers. A dataset for training an image-quality filter may need blur, glare and framing failures that a diagnostic benchmark intentionally excludes. A segmentation task may prioritize reliable lesion boundaries, while a longitudinal system may need repeated observations linked over time. Define success and required evidence before choosing a source. Public challenge participation demonstrates research activity, but it does not measure commercial procurement or prove a particular budget. A buyer’s requirement for real paired observations, specialist labels or device diversity should be evaluated directly. This guide does not infer demand from the number of images alone. A smaller, well-documented cohort can be more useful for a narrow evaluation than a much larger release with incompatible capture conditions or weak linkage. Label provenance, representation and uncertainty A useful schema separates the supplied diagnosis from how that diagnosis was established. Histopathology, follow-up, specialist consensus and other evidence can support different levels of confidence. Do not promote all labels to the same status simply because they fit one output taxonomy. Preserve uncertain, unconfirmed or excluded cases where the project needs them, and define whether the task is research classification, triage evaluation or another bounded objective. Representation should be described through supported fields rather than visual assumptions. Skin appearance depends on illumination, camera processing and body site as well as the person. If a project requires skin-tone or other cohort descriptors, establish how they were collected, defined and permitted for the use. A reviewer should not invent demographic facts from pixels to fill a coverage table. Document missing information and avoid claiming global representation from a collection’s international source list alone. A practical data dictionary A record should link original image, patient-group, lesion, encounter, acquisition type and diagnostic evidence. The buyer may not need direct personal identifiers; grouping can use appropriate project identifiers. Keep source-supplied fields distinct from normalized labels and newly added annotation. If a crop is derived from a larger photograph, preserve the original-image relationship and crop coordinates so the buyer can inspect context and prevent repeated-patient leakage. Annotation instructions should define whether a mask follows visible pigment, a clinical lesion boundary or a task-specific region. Hair, rulers, markers, gel bubbles and occlusions can matter differently for segmentation and classification. Record whether images were cleaned or cropped before annotation and check alignment after transformation. Metadata normalization should preserve the original category and mapping version, allowing a buyer to revise the taxonomy without losing the underlying source claim. Field Meaning to establish Review issue image_id / parent_image Original and derivative linkage Multiple crops counted as independent cases lesion_id / patient_group Related lesion and subject records Same lesion crosses evaluation boundaries capture_type Dermoscopy, close-up or other input Mixed acquisition styles hidden in one label diagnosis / evidence Label plus supporting method Weak and confirmed labels conflated encounter_date_relation Ordering or interval where permitted Upload date mistaken for clinical chronology quality_status Focus, glare, coverage and usability Poor examples silently removed from evaluation source/use_reference Release, license and project conditions Permission inferred from a mirror’s metadata Pricing and transparent workload models No representative public average for a commercial dermatology AI dataset license is established here. Access, cohort construction, paired acquisition, diagnostic linkage, specialist annotation and validation can be separate costs. Public benchmark access under specified conditions is not the same product as a project-specific commercial collection. A per-image price is especially hard to compare when several photographs represent one patient or lesion. For an illustrative workload calculation, suppose a project selects 1,500 lesion records with two images each. That is 3,000 files but 1,500 lesion units. If a technical pair/linkage check takes an assumed minute per lesion and specialist adjudication is budgeted at an assumed four minutes for fifteen percent, the work is twenty-five technical hours and fifteen specialist hours. These chosen times are a planning example, not evidence that they are sufficient for medical review. Apply separately quoted rates rather than one invented average. With hypothetical rates of $30 and $120 per hour respectively, those components total $2,550. The estimate excludes source rights, access arrangements, new collection, pathology linkage, privacy review, engineering, corrections and delivery. It is not a Fiund quote or observed price. A complete proposal should identify the accepted unit, label evidence, required capture types, specialist roles and what happens to uncertain records. This helps compare unlike collections without implying that every image has equal clinical value. Sample review, evaluation and failure cases Sample across acquisition types, body sites, devices, quality conditions and diagnostic categories relevant to the brief. Include difficult and uncertain cases intentionally. Review whether the evidence supports the label and whether pairing is reliable; do not assess the collection solely from attractive sample thumbnails. Check that visible rulers or ink markers do not become shortcuts for the target label, and inspect whether source-specific preprocessing creates easy distinctions unrelated to the clinical task. Keep patient groups together for new-patient evaluation. A split with different crops or views of the same lesion on both sides can inflate apparent generalization. If the project concerns transfer across devices or institutions, define an appropriate holdout and report its scope. For longitudinal work, preserve time order and distinguish observations before and after interventions where that information is available and appropriate. Technical acceptance does not establish clinical effectiveness; keep dataset review and any downstream product validation separate. A commercial route and a paired-lesion pilot [LXT’s medical-imaging service page](https://www.lxt.ai/datasets/medical-imaging/) lists dermatology among its advertised specialties. This is a commercial route to investigate, not evidence that a particular skin-image cohort is available, clinically validated or approved for the buyer’s use. No dermatology-specific transaction price is established by that page. Request a selected source description, capture types, grouping, label evidence and proposed terms rather than borrowing a generic medical-data price or vendor compliance claim. For a paired-lesion pilot, imagine one dermoscopic view, two clinical close-ups and a total-body crop associated with one lesion. The files can support several experiments, but they are not four independent patients. Review the links and the capture relationship, including whether views come from the same encounter. Keep missing or uncertain pairing explicit. A model may need broad surrounding context that a tightly cropped benchmark omits, or may require consistent scale absent from ordinary photographs. Compare sources using the clinical evidence actually attached to the label. A useful vendor response explains which records are source-supplied, which are normalized and which are independently reviewed for the project. It also identifies how image quality, repeated lesions and uncertain diagnoses affect acceptance. That is more informative than a single claim that all images are expert labeled. The pilot should expose those distinctions before a buyer scales annotation or assumes that a broad archive count represents the desired cohort. Providers, disclosed deals and a Fiund project brief Source routes can include public research releases under their terms, authorized clinical institutions, specialist imaging projects and commissioned collections where feasible. Their control of images, access process and evidence differ. An image vendor’s generic medical category does not establish a diagnostic cohort or permission for a particular model use. Ask which source records and specialist review would accompany the selected material before treating it as a suitable collection. No verified dermatology-image-specific AI-training license deal amount is established by the sources reviewed. Challenge prizes, research grants and clinical-software funding should not be presented as dataset prices. Send Fiund the input type, anatomy/body sites, task, evidence standard, grouping requirements, cohort constraints, labels and intended use. Fiund can assess potential source fit, sample-review needs and the scope of a project conversation. Availability, authorized access, permissions, preparation and pricing are confirmed for selected sources rather than guaranteed by the category page. Can all ISIC images be used under the same license? No. The official documentation identifies different release and image-level licenses. Keep the version, subset and actual terms attached to the files; do not apply a permissive subset’s terms to the whole archive. Is a lesion crop an independent patient? No. Several crops can originate from one image, lesion or patient. Preserve these relationships and choose the evaluation unit to match the research question. Does a high image count prove clinical diversity? No. Review independent subjects, acquisition conditions, label evidence and relevant cohort fields. Missing metadata should remain an explicit limitation rather than being inferred from appearance. Sources ISIC Challenge data by release: https://challenge.isic-archive.com/data/ ISIC licensing FAQ: https://www.isic-archive.com/blank-1 LXT custom medical imaging page: https://www.lxt.ai/datasets/medical-imaging/